Scholarlink

<p>Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Pharmacokinetics and Pharmacodynamics of Baxdrostat

  • 期刊论文

  • 发表日期：

    2024年12月31日

查看全文
  • Jessica Huston,
  • Dontia Orey,
  • Ashish Kumar,
  • Andrew Ashchi,
  • Andrea Ashchi,
  • Jason Berner,
  • Yazan Alkhouri,
  • David Sutton,
  • Wasim Deeb,
  • Mohannad Bisharat,
  • Rebecca F. Goldfaden

摘要

Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis inhibition, is currently being studied as a method to reduce blood pressure values in patients who are currently taking other antihypertensive medications. This review presents and discusses the current pharmacokinetic, pharmacodynamic, and clinical and scientific evidence pertaining to baxdrostat, a novel aldosterone synthase inhibitor.